BDMC protects AD in vitro via AMPK and SIRT1.

Research paper by Chenlin C Xu, Zijian Z Xiao, Heng H Wu, Guijuan G Zhou, Duanqun D He, Yunqian Y Chang, Yihui Y Li, Gang G Wang, Ming M Xie

Indexed on: 19 Dec '20Published on: 19 Dec '20Published in: Translational Neuroscience


Alzheimer's disease (AD) is a common neurodegenerative disorder without any satisfactory therapeutic approaches. AD is mainly characterized by the deposition of β-amyloid protein (Aβ) and extensive neuronal cell death. Curcumin, with anti-oxidative stress (OS) and cell apoptosis properties, plays essential roles in AD. However, whether bisdemethoxycurcumin (BDMC), a derivative of curcumin, can exert a neuroprotective effect in AD remains to be elucidated. In this study, SK-N-SH cells were used to establish an model to investigate the effects of BDMC on the Aβ-induced neurotoxicity. SK-N-SH cells were pretreated with BDMC and with or without compound C and EX527 for 30 min after co-incubation with rotenone for 24 h. Subsequently, western blotting, cell viability assay and SOD and GSH activity measurement were performed. BDMC increased the cell survival, anti-OS ability, AMPK phosphorylation levels and SIRT1 in SK-N-SH cells treated with Aβ. However, after treatment with compound C, an AMPK inhibitor, and EX527, an SIRT1inhibitor, the neuroprotective roles of BDMC on SK-N-SH cells treated with Aβ were inhibited. These results suggest that BDMC exerts a neuroprotective role on SK-N-SH cells via AMPK/SIRT1 signaling, laying the foundation for the application of BDMC in the treatment of neurodegenerative diseases related to AMPK/SIRT1 signaling. © 2020 Chenlin Xu et al., published by De Gruyter.

More like this: